TTRX (Turn Therapeutics) Research & Development: $0.37 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTRX Turn Therapeutics Inc TTRX
11 GF Score
Price $8.20
View Full Analysis

What is Turn Therapeutics Research & Development?

Turn Therapeutics TTRX +10.89% 11 Research & Development is $0.37 Mil as of Mar. 2026. GuruFocus rates TTRX with a GF Score™ of 11/100.

Research & Development is the aggregate amount of research and development expenses during the year. Turn Therapeutics's Research & Development for the three months ended in Mar. 2026 was $0.11 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.37 Mil.

Turn Therapeutics  (NAS:TTRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Turn Therapeutics Research & Development Related Terms

Turn Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Turn Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Turn Therapeutics Research & Development Chart

Turn Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
0.01 0.25 0.27

Turn Therapeutics Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only 0.01 0.06 0.16 0.04 0.11
TTRX
11GF Score
Turn Therapeutics Inc TTRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Turn Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.37 Mil mean?
Turn Therapeutics (TTRX) has a Research & Development of $0.37 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Turn Therapeutics and its competitors.
Is Turn Therapeutics' Research & Development too high?
Turn Therapeutics' current Research & Development is $0.37 Mil. Overall, Turn Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Turn Therapeutics' Research & Development compare to IRD and VRXA?
Turn Therapeutics' Research & Development of $0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Turn Therapeutics and its competitors. Turn Therapeutics's current Research & Development is $0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Turn Therapeutics stock overvalued right now?
Turn Therapeutics (TTRX) has a current Research & Development of $0.37 Mil. The current Research & Development is $0.37 Mil. Turn Therapeutics' overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Turn Therapeutics (TTRX), the current Research & Development is $0.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Turn Therapeutics Business Description

Address 250 North Westlake Boulevard, Suite 210, Westlake Village, CA, USA, 91362
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
11GF Score

Get the complete analysis for TTRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.20
Price